Aflibercept Biosimilar is a fusion protein commercialized by Teva Pharmaceutical Industries, with a leading Phase III program in Wet (Neovascular / Exudative) Macular Degeneration. According to Globaldata, it is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Aflibercept Biosimilar’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Aflibercept Biosimilar is expected to reach an annual total of $145 mn by 2040 globally based off GlobalData’s Revenue Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Aflibercept Biosimilar Overview
Teva Pharmaceutical Industries Overview
Teva Pharmaceutical Industries (Teva) discovers, develops, manufactures, and commercializes generic and specialty medicines. The company provides specialty medicines to treat disorders of the central nervous system (CNS), cancer, respiratory, dermatology, women’s health, and other disease conditions. It offers generic medicines in various dosage forms including capsules, tablets, injectables, liquids, inhalants, creams, and ointments. Teva also provides over-the-counter (OTC) products, besides active pharmaceutical ingredients (APIs). It also focuses on developing generic drugs. The company conducts its worldwide operations through a network of subsidiaries in regions such as North America, Europe, and international markets. Teva is headquartered in Tel Aviv, Israel.
The company reported revenues of (US Dollars) US$15,846 million for the fiscal year ended December 2023 (FY2023), an increase of 6.2% over FY2022. The operating profit of the company was US$433 million in FY2023, compared to an operating loss of US$2,197 million in FY2022. The net loss of the company was US$559 million in FY2023, compared to a net loss of US$2,446 million in FY2022.
The company reported revenues of US$4,164 million for the second quarter ended June 2024, an increase of 9% over the previous quarter.
For a complete picture of Aflibercept Biosimilar’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
